CTA
PGNX

Carillon Tower Advisers’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Carillon Tower Advisers’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,948,024
Closed -$20.1M – 493
2019
Q4 		$20.1M Hold
3,948,024
– – 0.13% 255
2019
Q3 		$20M Hold
3,948,024
– – 0.14% 250
2019
Q2 		$24.4M Hold
3,948,024
– – 0.17% 221
2019
Q1 		$18.3M Hold
3,948,024
– – 0.13% 259
2018
Q4 		$16.6M Hold
3,948,024
– – 0.14% 236
2018
Q3 		$24.7M Hold
3,948,024
– – 0.18% 204
2018
Q2 		$31.7M Hold
3,948,024
– – 0.25% 146
2018
Q1 		$28.1M Buy
3,948,024
+285,906
+8% +$1.9M 0.22% 162
2017
Q4 		$21.8M Buy
+3,662,118
New +$22.2M 0.23% 172

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Carillon Tower Advisers's PGNX Position: Q1 2020 in Review

Carillon Tower Advisers sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 3,948,024 shares — an estimated $20.1M sold.

Carillon Tower Advisers first reported a position in PGNX in Q4 2017 and held it in 9 quarters. The position peaked at $31.7M in Q2 2018. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Carillon Tower Advisers reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Carillon Tower Advisers sold 3,948,024 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $20.1M.
  • Carillon Tower Advisers first reported a position in Progenics Pharmaceuticals Inc in Q4 2017 and held it in 9 quarters.
  • Carillon Tower Advisers's Progenics Pharmaceuticals Inc position peaked at $31.7M in Q2 2018.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Carillon Tower Advisers's 13F filing for Q1 2020, filed 11 May 2020.